Stocklytics Platform
Asset logo for symbol IMUX
Immunic
IMUX56
$1.88arrow_drop_down3.33%-$0.06
Penny Stock
Asset logo for symbol IMUX
IMUX56

$1.88

arrow_drop_down3.33%

Performance History

Chart placeholder
Key Stats
Open$1.99
Prev. Close$1.95
EPS-1.50
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$145.02M
PE Ratio-
LOWHIGH
Day Range1.86
2.08
52 Week Range0.94
2.11
Ratios
Revenue-
EBITDA Margin %-
EPS-1.50

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Immunic (IMUX)

Immunic Inc (IMUX) is a biopharmaceutical company that focuses on developing innovative therapies for the treatment of chronic inflammatory and autoimmune diseases. The company's pipeline includes several drug candidates that target key components of the immune system to modulate and regulate the immune response. These candidates have the potential to address a range of indications, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis.
Immunic Inc's stock price history has shown significant growth over the past few years. In January 2017, the stock was trading around $3 per share, and by January 2021, it had reached a high of $30 per share. This steady increase in share price reflects the market's confidence in the company's pipeline and potential for future growth.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Daniel Vitt Ph.D.
Headquarters
New York
Employees
75
Exchange
NASDAQ
add Immunic  to watchlist

Keep an eye on Immunic

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Immunic 's (IMUX) price per share?

The current price per share for Immunic (IMUX) is $1.88. The stock has seen a price change of -$0.06 recently, indicating a -3.33% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Immunic (IMUX)?

For Immunic (IMUX), the 52-week high is $2.11, which is 11.94% from the current price. The 52-week low is $0.94, the current price is 99.47% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Immunic (IMUX) a growth stock?

Immunic (IMUX) has shown an average price growth of 0.41% over the past three years. It has received a score of 7 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Immunic as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Immunic (IMUX) stock price performance year to date (YTD)?

As of the latest data, Immunic (IMUX) has a year-to-date price change of 30%. Over the past month, the stock has experienced a price change of 26.51%. Over the last three months, the change has been 69.82%. Over the past six months, the figure is 42.8%. Looking at a longer horizon, the five-year price change stands at -87.11%.
help

Is Immunic (IMUX) a profitable company?

Immunic (IMUX) has a net income of -$93.61M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$99.22M. Furthermore, the EBITDA is -$93.53M.
help

What is the market capitalization of Immunic (IMUX)?

Immunic (IMUX) has a market capitalization of $145.03M. The average daily trading volume is 702.83K, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media